J Cancer 2020; 11(18):5432-5439. doi:10.7150/jca.44775 This issue

Research Paper

Combinational inhibition of EGFR and YAP reverses 5-Fu resistance in colorectal cancer

Changhao Huang1, Zihua Chen1, Chen Yang1, Lu Chen1, Chen Lai1, Yingying Zhang2, Weijie Yuan1✉, Ji-Hak Jeong3✉

1. Department of Gastrointestinal Surgery, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, China
2. Department of Oncology, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, China
3. Research Institute of Pharmaceutical Sciences, College of Pharmacy, Kyungpook National University, 80 Daehak-ro, Buk-gu, 41566, Daegu, Republic of Korea

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Citation:
Huang C, Chen Z, Yang C, Chen L, Lai C, Zhang Y, Yuan W, Jeong JH. Combinational inhibition of EGFR and YAP reverses 5-Fu resistance in colorectal cancer. J Cancer 2020; 11(18):5432-5439. doi:10.7150/jca.44775. Available from https://www.jcancer.org/v11p5432.htm

File import instruction

Abstract

Yes-associated protein (YAP) is a transcriptional coactivator that promotes cell proliferation, migration, and tissue homeostasis in colorectal cancer (CRC). Here, we established 5-Fu resistant CRC cell line (SW620R) and examined the role of YAP in chemotherapy resistance. We showed that YAP promoted cell proliferation, migration, and chemotherapy resistance in CRC. To increase efficacy of CRC treatment, we employed another therapeutic target EGFR which interacts with the upstream signaling molecules of YAP in Hippo pathway. Verteporfin, a YAP specific inhibitor, inhibits YAP activity by blocking the YAP-TEAD complex in the cell nucleus, and AG1478, an inhibitor of EGFR/ErbB1, induces the phosphorylation and degradation of YAP. We found that combinational inhibition of YAP by VP and AG1478 synergistically suppressed the CRC development and reversed chemotherapy resistance in vitro and in vivo. Therefore, our results demonstrated a novel therapeutic strategy, the combination of inhibitors targeting EGFR and YAP, to suppress and reverse chemotherapy resistance in colorectal cancer.

Keywords: colorectal cancer, YAP, chemotherapy resistance, EGFR, 5-Fu